FILGRASTIM
Overall Survival
Hospital General de Mexicoprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Overall Survival cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SUFENTANYL Peking University First Hospital | Phase 4 | BB |
ROPIVACAINE Peking University First Hospital | Phase 4 | BB |
Mebendazole Health Clinics Limited | Phase 3 | B |
Doxycycline Health Clinics Limited | Phase 3 | B |
Letrozole Jagiellonian University | D | |
Tucidinostat Sun Yat-sen University | N/A | D |
mln9708 RenJi Hospital | N/A | D |
Azacitidine Sun Yat-sen University | N/A | D |
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →